Lower post-transplant drug doses for older or unfit patients
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether giving a lower dose of cyclophosphamide after a bone marrow transplant can be safer for older or medically “unfit” patients, while still helping control blood cancers. It is designed for people who can’t tolerate the usual strongest transplant preparation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a blood cancer that qualifies for an allogeneic bone marrow transplant (for example AML in remission, certain ALL, myelodysplastic syndrome, myelofibrosis, CLL with specific genetics, or relapsed/progressing lymphoma).
- You’re age 60–85, or age 18–60 but not able to take the usual strongest “myeloablative” transplant preparation (for reasons like prior transplant, certain prior medicines, major organ problems, high transplant risk score, or low strength/energy).
- You need a suitable donor: a matched related donor, a half-matched (haploidentical) first-degree/collateral related donor, a matched unrelated donor, or a mismatched unrelated donor with at least a minimum HLA match level.
- Your general strength must be adequate (Karnofsky score 60 or higher), and you must be able to sign informed consent.
- Your heart, lung, kidney, and liver tests must meet minimum thresholds (the trial lists exact cutoffs, like ejection fraction, lung function, and creatinine clearance).
- You must agree to pregnancy prevention during the study and for at least 1 year after transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies giving donor lymphocyte (immune) infusions after a bone marrow transplant for people with high-risk blood cancers. The goal is to help the immune system better fight the cancer and improve outcomes after transplant.
This trial tests a standard transplant preparation (chemotherapy and low-dose radiation) followed by a special drug (PTCy) to prevent graft-versus-host disease after a donor stem cell transplant for blood cancers. It may help improve transplant success and reduce complications.
This trial tests a less intense type of bone marrow (stem cell) transplant from a partly matched family donor for people with high-risk solid tumors. It aims to lower treatment intensity while still using the donor’s immune system to help control the cancer.
This trial studies how well a donor bone marrow (stem cell) transplant works for people with inherited immune system problems (called immune deficiencies). It’s for patients who haven’t improved with usual treatment or don’t have another good option.
This early-phase study tests a lower dose of cyclophosphamide given after a stem cell transplant to prevent graft-versus-host disease (GVHD). It also uses sirolimus and mycophenolate to improve how well the donor immune system accepts the transplant, aiming to reduce side effects while keeping protection against GVHD.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
Hear when a new Hematologic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.